CombinatoRx founder Borisy heads new launch

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges

Funding drugs for rare diseases

MHT's Julie Donnelly: Life science startups finding investments

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

Oxford Immunotec taps Altieri as CFO [February 13, 2012]

VBI Vaccines pulls in $2.2M debt round [February 13, 2012]

Russian venture firm puts $100K into MassChallenge 2012 [February 10, 2012]

CombinatoRx Inc. founder and former CEO Alexis Borisy, who joined Third Rock Ventures as entrepreneur-in-residence in October, is heading up a new personalized medicine company known as Foundation Medicine, according to published reports.

Borisy led Cambridge-based CombinatoRx, which develops drug candidates for pain and inflammation, for almost 10 years before leaving in July. He joined Boston-based life sciences venture capital firm Third Rock in October. Third Rock has invested in companies including Afferent Pharmaceuticals Inc., Agios, Alnara Pharmaceuticals Inc., Constellation Pharmaeuticals Inc., DC Devices, Edimer Pharmaceuticals, Eleven Biotherapeutics, Ninepoint Medical, Seventh Sense Biosystems and Zafgen Inc.

Borisy told Xconomy that as entrepreneur-in-residence he works with other Third Rock team members to assess where the company should invest, but he offered few details about Foundation Medicine.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.